• Who we are
  • CD28 targeting
  • How it works

Terms of Use

NovImmune SA owns the copyright for the entire website. Content may not be used and copied in any other context. All liability claims for any information contained on this website are excluded. Logos and images may vary. Copying, using and modifying the contents of the website, even in part, requires the written consent of NovImmune SA.

New publication in ImmunoTherapy of Cancer

Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies

Read more

LinkedIn